P5091
SIGMA/SML0770 - ≥98% (HPLC)
Synonym: 1-
CAS Number: 882257-11-6
Empirical Formula (Hill Notation): C12H7Cl2NO3S2
Molecular Weight: 348.22
Linear Formula: C12H7Cl2NO3S2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | light yellow to dark yellow |
| form | powder |
| InChI | 1S/C12H7Cl2NO3S2/c1-6(16) |
| InChI key | LKZLGMAAKNEGCH-UHFFFAOYSA |
| Quality Level | 100  |
| solubility | DMSO: 10 mg/mL, clear |
| storage temp. | 2-8°C |
| Application: | P5091 has been used: • as a ubiquitin specific peptidase 47 (USP47) inhibitor in 3-(4,5-dimethylthiazol-2- • as a USP7 inhibitor to study the regulatory role for USP7 on inflammasome activation • as USP7 inhibitor in drug susceptibility assays to study its effect on bone marrow−resident tumor cells (BMRTCs)/ circulating tumor cells (CTCs) |
| Biochem/physiol Actions: | P5091 is a cell permeable, potent and specific inhibitor of deubiquitylating enzyme USP7 (Ubiquitin-Specific Protease-7) that induces HDM2 polyubiquitylation and accelerates degradation of HDM2. P5091 induces apoptosis in MM cells resistant to conventional and bortezomib therapies. P5091 inhibits tumor growth and prolongs survival in animal models of cancer. |
| Biochem/physiol Actions: | P5091 plays an important role in ovarian cancer, as it can prevent the growth of cells and can promote necrosis and apoptosis. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 - H413 |
| Precautionary statements | P273 - P301 + P310 + P330 |
| Hazard Codes | T |
| Risk Statements | 25 |
| Safety Statements | 45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |